固生堂(02273.HK)擬全球發售2787.8萬股 引入博裕等多家基石
格隆匯11月30日丨固生堂(02273.HK)發佈公告，公司擬全球發售2787.8萬股股份，其中香港發售股份278.78萬股，國際發售股份2509.02萬股，另有15%超額配股權；2021年11月30日至12月3日招股，預期定價日爲12月3日；發售價每股發售股份25.80港元-29.00港元，每手買賣單位100股，入場費約2929港元；BofA SECURITIES、及海通國際爲聯席保薦人；預期股份將於2021年12月10日於聯交所主板掛牌上市。
公司爲中國一家中醫醫療健康服務提供商。公司通過線下醫療機構及線上醫療健康平臺，爲客戶提供全面的中醫醫療健康服務及產品，以滿足客戶多樣化的醫療健康管理需求。根據弗若斯特沙利文的數據，按2020年提供醫療健康解決方案產生的總收入計，公司在中國的所有私營中醫醫療健康服務提供商中排名第八，在這一高度分散的市場中的市場份額爲0.6%(按收入計)。
公司已訂立基石投資協議，據此，基石投資者已同意按發售價認購或促使其指定的實體認購若幹數目的發售股份。基石投資者已同意按發售價認購可認購總額爲4200萬美元或約3.26億港元的有關數目的發售股份。按發售價每股發售股份27.40港元(即發售價範圍的中位數)計算，基石投資者將認購的股份總數爲1189.78萬股。基石投資者包括Foresight Funds(由東方資產管理(香港)有限公司全權管理)、Boyu、Sage Partners(並由銳智資本有限公司管理)、及UBS AM Singapore。
假設發售價爲每股發售股份27.40港元(即發售價範圍的中位數)，公司估計將獲得的全球發售所得款項淨額約爲6.631億港元。公司擬將全球發售所得款項淨額約69.8%用於拓展公司的線上線下業務，加強線上線下業務融合；約9.6%將用於加強公司的研發能力，當中約4.8%用於提升院內製劑的研發能力及約4.8%用於提升中醫解決方案包的研發能力；約9.6%將用於加強公司的供應鏈能力，包括根據業務擴張計劃升級現有煎藥中心及建立新煎藥中心，並根據業務需要在中長期內建立公司自有的GMP廠房；根據品牌推廣活動的一般費用，約4.9%將用於營銷及品牌推廣活動；及約6.0%將用於營運資金和一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
